血清CA125、Cyfra21-1和VEGF水平在非小细胞肺癌患者放化疗敏感性和预后评估中的应用价值

Application Value of Serum CA125,Cyfra21-1 and VEGF in Assessment of Chemoradiotherapy Sensibility and Prognosis in Non Small Cell Lung Cancer

目的 探讨血清CA125、Cyfra21-1和VEGF水平在非小细胞肺癌患者放化疗敏感性和预后评估中的应用价值。方法 回顾性分析100例非小细胞肺癌患者的临床资料。所有患者均接受NP方案(长春瑞滨+顺铂)联合放疗治疗。于放化疗前后采用酶联免疫吸附测定法(ELISA)检测患者血清CA125、Cyfra21-1和VEGF水平,并以同期于我院接受体检的30例健康体检者和30例的良性肺疾病患者作为对照,分析血清CA125、Cyfra21-1和VEGF水平与患者生存预后的相关性。结果 非小细胞肺癌患者血清CA125、Cyfra21-1和VEGF水平明显高于健康体检者和良性肺疾病患者的,差异有统计学意义(P<0.05);Pearson分析结果显示,非小细胞肺癌患者血清CA125、Cyfra21-1和VEGF水平与临床分期呈正相关,分期越高,其水平越高(γ值分别为0.354,0.523和0.418,P<0.05);CA125、Cyfra21-1和VEGF阴性患者的CBR显著高于CA125、Cyfra21-1和VEGF阳性患者的,差异有统计学意义(P<0.05)。Pearson分析结果显示,非小细胞肺癌患者放化疗前血清CA125、Cyfra21-1和VEGF水平与CBR呈负相关,其水平越高,则治疗的CBR越低(γ值分别为3.22、4.56和3.74,P<0.05);CA125、Cyfra21-1和VEGF阴性患者1、3年生存率明显高于CA125、Cyfra21-1和VEGF阳性患者的,差异有统计学意义(P<0.05)。Pearson分析结果显示,非小细胞肺癌患者放化疗前血清CA125、Cyfra21-1和VEGF水平与生存率呈负相关,其水平越高,则放化疗后1、3年生存率越低(γ值分别为2.86、4.21和3.58,P<0.05)。结论 血清CA125、Cyfra21-1和VEGF在非小细胞肺癌的发生发展中发挥重要的作用。放化疗前患者血清CA125、Cyfra21-1和VEGF可作为疗效及预后的评估指标。

Objective To application value of serum CA125,Cyfra21-1 and VEGF in assessment of chemoradiotherapy sensibility and prognosis in patients with non small cell lung cancer. Methods 100 patients with non small cell lung cancer were retrospectively analyzed. All patients accepted with NP regimen( vinorelbine + cisplatin). Detected serum CA125、Cyfra21-1 and VEGF levels with ELISA. And took 30 healthy examined people and 30 patients with benign pulmonary disease as control. Analyzed the correlation between CA125,Cyfra21-1,VEGF and clinical stages. Results The levels of CA125、Cyfra21-1 and VEGF in patients with non small cell lung cancer were higher than that in healthy examined people and patients with benign pulmonary disease,differecnces were statistically significance( P < 0. 05). Pearson analysis showed that non-small cell lung cancer patients serum CA125,Cyfra21-1 and VEGF levels were positively correlated to the clinical stages,the higher the installment,the higher levels( γ = 0. 354,0. 523 and 0. 418,P < 0. 05). The CBR in negative patients of CA125、Cyfra21-1 and VEGFwere higher than that in positive patients,differecnces were statistically significance( P < 0. 05). Pearson analysis showed that non-small cell lung cancer patients serum CA125,Cyfra21-1 and VEGF levels before chemoradiotherapy were negatively correlated to the CBR,the higher levels,the lower CBR( γ = 3. 22,4. 56 and 3. 74,P < 0. 05). The 1,3 year survival rate in negative patients of CA125、Cyfra21-1 and VEGFwere more over than that in positive patients,differecnces were statistically significant( P < 0. 05). Pearson analysis showed that non-small cell lung cancer patients serum CA125,Cyfra21-1 and VEGF levels before chemoradiotherapy were negatively correlated to the survival rate,the higher levels,the lower 1,3 year survival rate. Conclusion The CA125、Cyfra21-1 and VEGF play an important role in development and progression of development and progression. The levels of CA125、Cyfra21-1 and VEGF before chemoradiotherapycan be used as the evaluation of curative effect and prognosis.